[
  {
    "title": "港股异动 | 荣昌生物AH股齐涨 新药临床研究申请获国家药监局批准",
    "href": "http://stock.jrj.com.cn/2023/01/04100237257526.shtml",
    "datetime": "2023-01-04 10:02:37",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：向188名激励对象授予286.945万股A股限制性股票",
    "href": "http://stock.jrj.com.cn/2022/12/28192037244031.shtml",
    "datetime": "2022-12-28 19:20:04",
    "code": "688331"
  },
  {
    "title": "荣昌生物AH齐涨 RC118获美国FDA两项孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2022/12/09104537200641.shtml",
    "datetime": "2022-12-09 10:45:31",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：RC118用于治疗胃癌(包括胃食管交接癌)及胰腺癌均获FDA颁发孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2022/12/08183937199055.shtml",
    "datetime": "2022-12-08 18:39:54",
    "code": "688331"
  },
  {
    "title": "荣昌生物：FDA同意泰它西普在美国开展IgA肾病适应症的Ⅲ期临床试验",
    "href": "http://stock.jrj.com.cn/2022/11/19110037151985.shtml",
    "datetime": "2022-11-19 11:00:37",
    "code": "688331"
  },
  {
    "title": "再获重磅认定 荣昌生物泰它西普正式纳入突破性治疗品种",
    "href": "http://stock.jrj.com.cn/2022/11/17162037146953.shtml",
    "datetime": "2022-11-17 16:20:19",
    "code": "688331"
  },
  {
    "title": "港股异动 | 荣昌生物AH齐涨 CDE拟授予泰它西普突破性治疗药物认定用于治疗全身型重症肌无力",
    "href": "http://stock.jrj.com.cn/2022/11/11095437130080.shtml",
    "datetime": "2022-11-11 09:54:19",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：RongChang Holding Group及I-NOVA已合计减持658.0346万股H股",
    "href": "http://stock.jrj.com.cn/2022/11/10201437128902.shtml",
    "datetime": "2022-11-10 20:14:04",
    "code": "688331"
  },
  {
    "title": "荣昌生物：新增一线治疗晚期尿路上皮癌 维迪西妥单抗获新版CSCO指南全线治疗推荐",
    "href": "http://stock.jrj.com.cn/2022/11/06142637115136.shtml",
    "datetime": "2022-11-06 14:26:51",
    "code": "688331"
  },
  {
    "title": "荣昌生物：泰它西普治疗全身型重症肌无力Ⅱ期研究数据公布",
    "href": "http://stock.jrj.com.cn/2022/10/31140737099528.shtml",
    "datetime": "2022-10-31 14:07:24",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：第三季度净亏损1.99亿元",
    "href": "http://stock.jrj.com.cn/2022/10/27160437089674.shtml",
    "datetime": "2022-10-27 16:04:44",
    "code": "688331"
  },
  {
    "title": "港股异动 | 荣昌生物AH股继续拉升 H股大涨15% 机构唱好",
    "href": "http://stock.jrj.com.cn/2022/10/18151037063817.shtml",
    "datetime": "2022-10-18 15:10:21",
    "code": "688331"
  },
  {
    "title": "荣昌生物-B(09995.HK)将于10月27日举行董事会会议以审批前三季度业绩",
    "href": "http://stock.jrj.com.cn/2022/10/17163737060667.shtml",
    "datetime": "2022-10-17 16:37:06",
    "code": "688331"
  },
  {
    "title": "荣昌生物2022年股票激励计划出炉：多名实控人及配偶、儿子均为激励对象",
    "href": "http://stock.jrj.com.cn/2022/10/17111137059647.shtml",
    "datetime": "2022-10-17 11:11:13",
    "code": "688331"
  },
  {
    "title": "港股异动 | 利好叠加 荣昌生物AH股再度拉升 H股一度大涨超12%",
    "href": "http://stock.jrj.com.cn/2022/10/17101937059458.shtml",
    "datetime": "2022-10-17 10:19:51",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)拟推358万股限制性股票激励计划",
    "href": "http://stock.jrj.com.cn/2022/10/17093037059293.shtml",
    "datetime": "2022-10-17 09:30:08",
    "code": "688331"
  },
  {
    "title": "港股异动 | 荣昌生物AH股均大涨 H股劲升超12%",
    "href": "http://stock.jrj.com.cn/2022/10/14102537054973.shtml",
    "datetime": "2022-10-14 10:25:51",
    "code": "688331"
  },
  {
    "title": "荣昌生物：泰它西普获FDA孤儿药资格认定 用于治疗重症肌无力",
    "href": "http://stock.jrj.com.cn/2022/10/13152837052816.shtml",
    "datetime": "2022-10-13 15:28:18",
    "code": "688331"
  },
  {
    "title": "港股异动 | 荣昌生物涨7% 泰它西普获美国FDA孤儿药资格认定",
    "href": "http://stock.jrj.com.cn/2022/10/13095337051933.shtml",
    "datetime": "2022-10-13 09:53:39",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331)：公司使用募集资金置换预先投入的自筹资金",
    "href": "http://stock.jrj.com.cn/2022/09/27091737023664.shtml",
    "datetime": "2022-09-27 09:17:28",
    "code": "688331"
  },
  {
    "title": "港股异动丨荣昌生物AH股齐涨 H股大幅反弹近13%",
    "href": "http://stock.jrj.com.cn/2022/09/26105737020660.shtml",
    "datetime": "2022-09-26 10:57:01",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：223.2987万股限售股将于9月30日解禁",
    "href": "http://stock.jrj.com.cn/2022/09/23181437017851.shtml",
    "datetime": "2022-09-23 18:14:34",
    "code": "688331"
  },
  {
    "title": "港股异动丨荣昌生物AH股齐升 泰它西普达到初步数据结果 有效率达82.6%",
    "href": "http://stock.jrj.com.cn/2022/09/20101037007169.shtml",
    "datetime": "2022-09-20 10:10:56",
    "code": "688331"
  },
  {
    "title": "荣昌生物：泰它西普国内SLE Ⅲ期确证性研究初步数据公布 有效率高达82.6%",
    "href": "http://stock.jrj.com.cn/2022/09/19181537005677.shtml",
    "datetime": "2022-09-19 18:15:23",
    "code": "688331"
  },
  {
    "title": "近10日370家公司获机构调研 荣昌生物最受关注",
    "href": "http://stock.jrj.com.cn/hotstock/2022/09/16082636999195.shtml",
    "datetime": "2022-09-16 08:26:32",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：上半年净亏损4.89亿元",
    "href": "http://stock.jrj.com.cn/2022/08/30192036954041.shtml",
    "datetime": "2022-08-30 19:20:55",
    "code": "688331"
  },
  {
    "title": "港股异动丨荣昌生物AH股继续拉升 A股大涨13%创上市新高",
    "href": "http://stock.jrj.com.cn/2022/08/05101136872858.shtml",
    "datetime": "2022-08-05 10:11:18",
    "code": "688331"
  },
  {
    "title": "港股异动丨荣昌生物AH股齐升 H股大涨10%",
    "href": "http://stock.jrj.com.cn/2022/08/04103936869480.shtml",
    "datetime": "2022-08-04 10:39:15",
    "code": "688331"
  },
  {
    "title": "港股异动丨荣昌生物AH股齐涨 H股一度大涨逾12%创3个月新高",
    "href": "http://stock.jrj.com.cn/2022/07/06100136786107.shtml",
    "datetime": "2022-07-06 10:01:59",
    "code": "688331"
  },
  {
    "title": "全球同步开发进入快速推进阶段 荣昌生物泰它西普SLE全球多中心Ⅲ期临床完成首例患者入组给药",
    "href": "http://stock.jrj.com.cn/2022/06/23130836752729.shtml",
    "datetime": "2022-06-23 13:08:55",
    "code": "688331"
  },
  {
    "title": "小摩：予荣昌生物-B“增持”评级，目标价58港元",
    "href": "http://stock.jrj.com.cn/2022/05/06141736579642.shtml",
    "datetime": "2022-05-06 14:17:29",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：控股股东、实控人及部分董监高等延长股份锁定期",
    "href": "http://stock.jrj.com.cn/2022/05/05192536571329.shtml",
    "datetime": "2022-05-05 19:25:05",
    "code": "688331"
  },
  {
    "title": "荣昌生物2022年第一季度亏损2.87亿 产品销售成本增加",
    "href": "http://stock.jrj.com.cn/2022/05/03175136545418.shtml",
    "datetime": "2022-05-03 17:51:04",
    "code": "688331"
  },
  {
    "title": "荣昌生物-B2022年首季亏损2.87亿元，亏损同比扩大55.48%",
    "href": "http://stock.jrj.com.cn/2022/04/28155336493105.shtml",
    "datetime": "2022-04-28 15:53:31",
    "code": "688331"
  },
  {
    "title": "荣昌生物一季报：营收超2021年全年 多维度拓宽“护城河”",
    "href": "http://stock.jrj.com.cn/2022/04/27224836487774.shtml",
    "datetime": "2022-04-27 22:48:59",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)一季度净亏损2.87亿元",
    "href": "http://stock.jrj.com.cn/2022/04/27161936484416.shtml",
    "datetime": "2022-04-27 16:19:35",
    "code": "688331"
  },
  {
    "title": "荣昌生物-B(09995.HK)斥3.4亿元购买理财产品",
    "href": "http://stock.jrj.com.cn/2022/04/20213936412993.shtml",
    "datetime": "2022-04-20 21:39:49",
    "code": "688331"
  },
  {
    "title": "科创板新股荣昌生物开盘破发 跌4.17%",
    "href": "http://stock.jrj.com.cn/2022/03/31093036228893.shtml",
    "datetime": "2022-03-31 09:30:08",
    "code": "688331"
  },
  {
    "title": "中国生物药界“新贵”高歌猛进 荣昌生物登陆科创板开启“A+H”时代",
    "href": "http://stock.jrj.com.cn/2022/03/31005536237114.shtml",
    "datetime": "2022-03-31 00:55:47",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：将于3月31日在科创板上市",
    "href": "http://stock.jrj.com.cn/2022/03/29211036158323.shtml",
    "datetime": "2022-03-29 21:10:31",
    "code": "688331"
  },
  {
    "title": "荣昌生物-B(09995.HK)：回拨机制启动后A股网上发行最终中签率为0.03784759%",
    "href": "http://stock.jrj.com.cn/2022/03/28181235905810.shtml",
    "datetime": "2022-03-28 18:12:26",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)披露中签结果：中签号码共有2.61万个",
    "href": "http://stock.jrj.com.cn/2022/03/23190934871380.shtml",
    "datetime": "2022-03-23 19:09:00",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)：回拨后网上发行最终中签率为0.03784759%",
    "href": "http://stock.jrj.com.cn/2022/03/22190534861769.shtml",
    "datetime": "2022-03-22 19:05:07",
    "code": "688331"
  },
  {
    "title": "荣昌生物(688331.SH)IPO定价为48元/股 3月22日申购",
    "href": "http://stock.jrj.com.cn/2022/03/20170634852175.shtml",
    "datetime": "2022-03-20 17:06:16",
    "code": "688331"
  },
  {
    "title": "上榜“金智奖”！荣昌生物获中国医药生物产业优秀商业实践奖",
    "href": "http://stock.jrj.com.cn/2021/12/31090034090852.shtml",
    "datetime": "2021-12-31 09:00:06",
    "code": "688331"
  },
  {
    "title": "荣昌生物过会：今年IPO过关第361家 华泰联合证券过26.5单",
    "href": "http://stock.jrj.com.cn/2021/11/12095233840031.shtml",
    "datetime": "2021-11-12 09:52:00",
    "code": "688331"
  },
  {
    "title": "宣泰医药科创板IPO遭暂缓审议，荣昌生物成功过审",
    "href": "http://stock.jrj.com.cn/2021/11/12090933839763.shtml",
    "datetime": "2021-11-12 09:09:41",
    "code": "688331"
  },
  {
    "title": "二次上市回科创板问询，荣昌生物如是解答这几个问题",
    "href": "http://stock.jrj.com.cn/2021/10/21093833725544.shtml",
    "datetime": "2021-10-21 09:38:19",
    "code": "688331"
  },
  {
    "title": "是否存在市场容量有限的风险？ 荣昌生物科创板IPO首轮连遭18问",
    "href": "http://stock.jrj.com.cn/2021/09/08094033402513.shtml",
    "datetime": "2021-09-08 09:40:03",
    "code": "688331"
  },
  {
    "title": "港股医药板块上扬，荣昌生物-B盘中暴涨超40%，恒生医疗ETF(513060)涨1.6%",
    "href": "http://stock.jrj.com.cn/2021/08/10105433230530.shtml",
    "datetime": "2021-08-10 10:54:25",
    "code": "688331"
  },
  {
    "title": "业绩亏损谋求二次上市 荣昌生物冲刺科创板获问询",
    "href": "http://stock.jrj.com.cn/2021/07/16112533106560.shtml",
    "datetime": "2021-07-16 11:25:25",
    "code": "688331"
  },
  {
    "title": "鲁泰A：荣昌生物上市前进行了股份转增 因此公司持有其股份增加",
    "href": "http://stock.jrj.com.cn/2021/06/22143432976091.shtml",
    "datetime": "2021-06-22 14:34:28",
    "code": "688331"
  },
  {
    "title": "亟需二次上市“补血”？荣昌生物：三年亏损近14亿 港股上市不到半年奔“科”",
    "href": "http://stock.jrj.com.cn/2021/06/22091432974346.shtml",
    "datetime": "2021-06-22 09:14:57",
    "code": "688331"
  },
  {
    "title": "鲁泰A：公司目前持有荣昌生物四百多万股",
    "href": "http://stock.jrj.com.cn/2021/06/17211332949800.shtml",
    "datetime": "2021-06-17 21:13:11",
    "code": "688331"
  },
  {
    "title": "三年亏损近14亿奔“科” 荣昌生物谋求“A+H”两地上市",
    "href": "http://stock.jrj.com.cn/2021/06/09092532897782.shtml",
    "datetime": "2021-06-09 09:25:04",
    "code": "688331"
  },
  {
    "title": "港股上市4个月股价大涨64%，荣昌生物启动A股二次上市",
    "href": "http://stock.jrj.com.cn/2021/03/09135732097353.shtml",
    "datetime": "2021-03-09 13:57:55",
    "code": "688331"
  },
  {
    "title": "荣昌生物启动辅导拟A股二次上市，去年港股上市曾创当年全球最大生物医药IPO",
    "href": "http://stock.jrj.com.cn/ipo/2021/03/09090732095650.shtml",
    "datetime": "2021-03-09 09:07:50",
    "code": "688331"
  },
  {
    "title": "荣昌生物ADC药物或被药监局纳入突破性治疗品种",
    "href": "http://stock.jrj.com.cn/2020/12/18202631521517.shtml",
    "datetime": "2020-12-18 20:26:00",
    "code": "688331"
  },
  {
    "title": "荣昌生物今日正式通过港交所聆讯 沃森生物前三季度归母净利润增长超260％ | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/10/21185731101986.shtml",
    "datetime": "2020-10-21 18:57:29",
    "code": "688331"
  },
  {
    "title": "鲁泰A：转让所持荣昌生物部分出资额",
    "href": "http://stock.jrj.com.cn/2020/03/06185428969450.shtml",
    "datetime": "2020-03-06 18:54:00",
    "code": "688331"
  }
]